Clinical trial · Observational
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
NCT00681369CI-TRIAL-00004328completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
Primary outcomes (2)
- measure
- Evaluate Faslodex therapeutic strategy and treatment duration
- timeFrame
- At the end of the study
- measure
- Describe the characteristics of patients treated with Faslodex
- timeFrame
- At the end of the study
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
References
Publications (0)
Data not yet available
No reference posted for this study.